Cell No. : Cell Name
RCB1549 : YSCCC
update : 2023/11/20
|
| Comment | Human cell line derived from cholangiocellular carcinoma. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Imanishi, Hiroyasu
|
| Originator |
Imanishi, Hiroyasu
|
| Year of deposit |
1999
|
| Another name |
CCC
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Female
|
| Age at sampling |
70 years
|
| Tissue |
liver, ascites meta
|
| Disease name |
cholangiocellular carcinoma
|
| Metastastatic ability |
Yes
|
| Metastatsd tissue |
ascites
|
| Classification |
cancer
|
|
Lifespan |
infinite
|
| Morphology |
lymphocyte-like
|
| Cellosaurus(Expasy) |
CVCL_3629
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent/Suspension cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
| SC frequency |
|
Subculture : once/2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Virus (HBV) |
|
(-)
|
| Virus (HCV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
65-73(50) : /67(5),68(8),69(10),70(11),71(8),72(4)/
|
| STR(human) |
|
OK
|
|
deposit info
|
|
|
lot info
|
| D5S818 |
D13S317 |
D7S820 |
D16S539 |
vWA |
TH01 |
Amelogenin |
TPOX |
CSF1PO |
|
10,12
|
12
|
10,11
|
10,11
|
16,17
|
7,9
|
X
|
11
|
10,11
|
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
0
|
| User's Publication |
9
|
| User's Publication |
|
13485
Hirata H, Kuwatani M, Nakajima K, Kodama Y, Yoshikawa Y, Ogawa M, Sakamoto N.
Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes
Cancer Sci
2021
112(2):828-838
PubMed ID: 33345417
DOI: 10.1111/cas.14780
|
|
16101
Nattawan Suwannakul, Napat Armartmuntree, Raynoo Thanan, Kaoru Midorikawa, Tetsuo Kon, Shinji Oikawa, Hatasu Kobayashi, Ning Ma, Shosuke Kawanishi, Mariko Murata
Targeting fructose metabolism by glucose transporter 5 regulation in human cholangiocarcinoma
Genes & Diseases
2021
PubMed ID: 36157482
DOI: 10.1016/j.gendis.2021.09.002
|
|
10658
Yokoi K, Kobayashi A, Motoyama H, Kitazawa M, Shimizu A, Notake T, Yokoyama T, Matsumura T, Takeoka M, Miyagawa SI.
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Oncol. Rep.
2018
39:843-850
PubMed ID: 29251327
DOI: 10.3892/or.2017.6153
|
|
14913
Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS.
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
Dis Model Mech
2018
11(8):dmm03305
PubMed ID: 29666220
DOI: 10.1242/dmm.033050
|
|
3735
Saha SK et al
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Cancer Discov
2016
6(7):727-39
PubMed ID: 27231123
DOI: 10.1158/2159-8290.CD-15-1442
|
|
3709
Kawamoto T, Ishige K, Thomas M, Yamashita-Kashima Y, Shu S, Ishikura N, Ariizumi S, Yamamoto M, Kurosaki K, Shoda J.
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
J Gastroenterol
2015
50(4):467-79
PubMed ID: 25112701
DOI: 10.1007/s00535-014-0984-5
|
|
7862
Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
J Hepatobiliary Pancreat Sci
2011
18:700-11
PubMed ID: 21451941
DOI: 10.1007/s00534-011-0376-7
|
|
7938
Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, Yamamoto M, Hyodo I, Shoda J.
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
J. Gastroenterol.
2011
46:779-89
PubMed ID: 21331764
DOI: 10.1007/s00535-011-0380-3
|
|
13665
Kamigaki M, Sasaki T, Serikawa M, Inoue M, Kobayashi K, Itsuki H, Minami T, Yukutake M, Okazaki A, Ishigaki T, Ishii Y, Kosaka K, Chayama K.
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells
Int J Oncol
2011
39(3):561-8
PubMed ID: 21687941
DOI: 10.3892/ijo.2011.1087
|
Back
Top
CELL BANK Website